Case of severe thrombocytopenia with recurrent extensive deep vein thrombosis due to antiphospholipid syndrome, management challenge

Severe thrombocytopenia in secondary antiphospholipid syndrome (APS) presents a significant management challenge. This case highlights the complexity of managing APS-related thrombocytopenia, requiring a nuanced approach to balancing bleeding and thrombotic risks. Intravenous immunoglobulin, followed by a short course of steroids, successfully increased platelet counts without adverse bleeding or thrombotic events. Initiating therapeutic anticoagulation with Warfarin was delayed until platelet counts exceeded 50 × 10^3/μL, emphasizing the cautious approach required in such cases to mitigate thrombotic risks while avoiding bleeding complications.

Authors

Institutions

Publication Details

Journal
Clinical Case Reports
Published
2025-02-01
DOI
https://doi.org/10.1002/ccr3.9430
Citations
2
Primary Topic
Platelet Disorders and Treatments
Type
article
Field-Weighted Citation Impact
3.54

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Case of severe thrombocytopenia with recurrent extensive deep vein thrombosis due to antiphospholipid syndrome, management challenge

Arshad Ali, Bassem Al Hariri, Mohamed Mohamedali, Memon Noor Illahi et al.
2 citations
Clinical Case Reports
Platelet Disorders and Treatments
3.54
article

Case of severe thrombocytopenia with recurrent extensive deep vein thrombosis due to antiphospholipid syndrome, management challenge

Arshad Ali, Bassem Al Hariri, Mohamed Mohamedali, Memon Noor Illahi, Greta Alì, Muhammad Sharif, Feroz Jenner Poolakundan
article en
2 citations

Abstract

Severe thrombocytopenia in secondary antiphospholipid syndrome (APS) presents a significant management challenge. This case highlights the complexity of managing APS-related thrombocytopenia, requiring a nuanced approach to balancing bleeding and thrombotic risks. Intravenous immunoglobulin, followed by a short course of steroids, successfully increased platelet counts without adverse bleeding or thrombotic events. Initiating therapeutic anticoagulation with Warfarin was delayed until platelet counts exceeded 50 × 10^3/μL, emphasizing the cautious approach required in such cases to mitigate thrombotic risks while avoiding bleeding complications.

Clinical Case ReportsVol. 13(2)
Weill Cornell Medical College in Qatar (QA), Hamad Medical Corporation (QA), Qatar University (QA)
Hamad Medical Corporation, Qatar National Library
Good health and well-being
Openalex Percentile: Top 9%
Platelet Disorders and Treatments
3.54
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.